Effect of the Antioxidant Lipoic Acid in Aortic Phenotype in a Marfan Syndrome Mouse Model

Table 4

Evolution of echocardiographic parameters in WT and MFS mice with 6 months of age after losartan or lipoic acid treatments.

	Untreated		Losartan treatment		Lipoic acid treatment
	WT6	MFS6	WT6	MFS6	WT6	MFS6
	()	()	()	()	()	()
Ao/BW (mm/mg)	47 ± 1	63 ± 3^a	47 ± 1^e	58 ± 2^f	42 ± 2^b,c	60 ± 2^f,g
LVEDD (mm)	3.3 ± 0.1	3.5 ± 0.1	3.4 ± 0.1	3.2 ± 0.1	3.9 ± 0.2^k	4.4 ± 0.2^a,e,i,j
LVESD (mm)	1.9 ± 0.1	2.0 ± 0.1	2.2 ± 0.1	2.0 ± 0.1	2.4 ± 0.2	2.2 ± 0.1
IVST (mm)	0.7 ± 0.1	0.9 ± 0.1	0.6 ± 0.1	0.6 ± 0.1	0.8 ± 0.1	0.9 ± 0.1^c,d
PWT (mm)	0.7 ± 0.1	0.9 ± 0.1	0.6 ± 0.1^e	0.6 ± 0.1^e	0.8 ± 0.1^h,k	1.0 ± 0.1^a,i,j
FS (%)	41 ± 1	43 ± 2	37 ± 2	38 ± 2	38 ± 3	40 ± 2
EF (%)	78 ± 1	79 ± 2	72 ± 3	75 ± 2	74 ± 3	77 ± 2
E/A ratio	1.9 ± 0.1	1.2 ± 0.1^a	2.5 ± 0.2^b	1.4 ± 0.1^a,i	1.8 ± 0.1	1.3 ± 0.1^f,i

WT: wild type; MFS: Marfan syndrome; 6: 6 months of age; Ao/BW: aortic root diameter index; LVEDD: left ventricular end-diastolic diameters; LVESD: left ventricular end- systolic diameters; IVST: interventricular septal thickness; PWT: posterior wall thickness; FS: fractional shortening; EF: ejection fraction; E/A: E/A waves; ^a versus untreated WT6; ^b versus untreated MFS6; ^c versus losartan treatment MFS6; ^d versus losartan treatment WT6; ^e versus untreated MFS6; ^f versus untreated WT6; ^g versus lipoic acid treatment WT6; ^h versus losartan treatment WT6; ⁱ versus losartan treatment WT6; ^j versus losartan treatment MFS6; ^k versus losartan treatment MFS6.